旨在更好地理解去甲基化药物和维奈托克疗法。 - Suppr | 超能文献

Toward an improved understanding of hypomethylating agent and venetoclax therapies.

作者信息

DiNardo Courtney D

机构信息

Department of Leukemia, UT MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Am J Hematol. 2024 Feb;99(2):152-154. doi: 10.1002/ajh.27178. Epub 2023 Dec 15.

DOI:10.1002/ajh.27178

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Toward an improved understanding of hypomethylating agent and venetoclax therapies.旨在更好地理解去甲基化药物和维奈托克疗法。

Am J Hematol. 2024 Feb;99(2):152-154. doi: 10.1002/ajh.27178. Epub 2023 Dec 15.

2

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

3

Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.维奈克拉联合地西他滨或阿扎胞苷简化方案治疗急性髓系白血病

Leuk Res. 2023 Nov;134:107370. doi: 10.1016/j.leukres.2023.107370. Epub 2023 Aug 16.

4

Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?维奈克拉联合去甲基化药物治疗两名老年急性髓系白血病患者的长期疗效：是否到了采用治疗中断策略的时候？

Ann Hematol. 2024 May;103(5):1787-1788. doi: 10.1007/s00277-024-05700-4. Epub 2024 Mar 9.

5

Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.维奈托克联合低甲基化药物治疗复发/难治性急性髓系白血病：来自单中心的病例系列。

J BUON. 2021 Sep-Oct;26(5):2026-2032.

6

Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.地西他滨和西扎珠苷加维奈克拉的全口服方案：老年或身体状况不佳的急性髓系白血病患者的新进展。

Lancet Haematol. 2024 Apr;11(4):e245-e246. doi: 10.1016/S2352-3026(24)00060-7. Epub 2024 Mar 4.

7

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.使用地西他滨/维奈克拉和达雷妥尤单抗治疗与治疗相关的急性髓系白血病及潜在的多发性骨髓瘤。

Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13.

8

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.一项在门诊环境中进行的 Venetoclax 联合阿扎胞苷或地西他滨治疗急性髓系白血病患者的 3b 期研究。

Hematol Oncol. 2024 May;42(3):e3274. doi: 10.1002/hon.3274.

9

Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.低甲基化药物联合维奈托克治疗急性髓系白血病：临床试验数据更新及实际应用注意事项。

Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13.

10

[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].维奈托克联合阿扎胞苷治疗老年急性髓系白血病或髓系肉瘤：三例报告及文献综述

Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):694-696. doi: 10.3760/cma.j.issn.0253-2727.2020.08.016.

引用本文的文献

1

Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.老年急性髓系白血病：从新的生物学见解到靶向治疗。

Curr Oncol. 2024 Oct 24;31(11):6632-6658. doi: 10.3390/curroncol31110490.